Centessa Pharmaceuticals (CNTA) News Today $16.63 -0.12 (-0.72%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$16.62 0.00 (-0.03%) As of 02/21/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Insider Selling: Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Sells 55,000 Shares of StockCentessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) CEO Saurabh Saha sold 55,000 shares of the stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $15.93, for a total value of $876,150.00. Following the transaction, the chief executive officer now owns 331,017 shares of the company's stock, valued at $5,273,100.81. This represents a 14.25 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.February 21 at 8:38 PM | marketbeat.comInsider Selling: Centessa Pharmaceuticals plc (NASDAQ:CNTA) General Counsel Sells 6,000 Shares of StockCentessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) General Counsel Iqbal J. Hussain sold 6,000 shares of the stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $16.18, for a total value of $97,080.00. Following the sale, the general counsel now owns 105,386 shares in the company, valued at approximately $1,705,145.48. This trade represents a 5.39 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.February 20 at 8:34 PM | marketbeat.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) Short Interest UpdateCentessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) was the target of a significant decline in short interest in the month of January. As of January 31st, there was short interest totalling 3,050,000 shares, a decline of 7.3% from the January 15th total of 3,290,000 shares. Approximately 3.4% of the company's shares are sold short. Based on an average daily volume of 678,600 shares, the short-interest ratio is currently 4.5 days.February 18, 2025 | marketbeat.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) Given Consensus Rating of "Buy" by AnalystsFebruary 16, 2025 | americanbankingnews.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) Receives Consensus Recommendation of "Buy" from BrokeragesShares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) have been given an average recommendation of "Buy" by the seven brokerages that are currently covering the stock, Marketbeat reports. Seven investment analysts have rated the stock with a buy recommendation. The average 12 montFebruary 16, 2025 | marketbeat.comKaren M. Anderson Sells 30,526 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) StockFebruary 11, 2025 | insidertrades.comCentessa Pharmaceuticals officer sells shares worth $588,943February 10, 2025 | msn.comInsider Selling: Centessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Sells 30,526 Shares of StockCentessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) insider Karen M. Anderson sold 30,526 shares of the firm's stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $19.03, for a total value of $580,909.78. Following the sale, the insider now directly owns 54,322 shares of the company's stock, valued at $1,033,747.66. This represents a 35.98 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.February 10, 2025 | marketbeat.comCentessa Pharmaceuticals (NASDAQ:CNTA) Trading Down 5.3% - What's Next?Centessa Pharmaceuticals (NASDAQ:CNTA) Shares Down 5.3% - Time to Sell?February 10, 2025 | marketbeat.comCentessa Pharmaceuticals (NASDAQ:CNTA) Given Buy Rating at GuggenheimGuggenheim restated a "buy" rating on shares of Centessa Pharmaceuticals in a research report on Monday.February 10, 2025 | marketbeat.comCentessa Pharmaceuticals (NASDAQ:CNTA) Sets New 12-Month High - What's Next?Centessa Pharmaceuticals (NASDAQ:CNTA) Hits New 1-Year High - Still a Buy?February 7, 2025 | marketbeat.comCentessa Pharmaceuticals officer Tia Bush sells $185,406 in sharesFebruary 5, 2025 | msn.comKaren M. Anderson Sells 6,471 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) StockFebruary 5, 2025 | insidertrades.comKaren M. Anderson Sells 6,471 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) StockCentessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) insider Karen M. Anderson sold 6,471 shares of Centessa Pharmaceuticals stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $16.86, for a total value of $109,101.06. Following the transaction, the insider now directly owns 54,322 shares of the company's stock, valued at approximately $915,868.92. This represents a 10.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.February 4, 2025 | marketbeat.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) CTO Sells $185,460.00 in StockCentessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) CTO Tia L. Bush sold 11,000 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $16.86, for a total transaction of $185,460.00. Following the sale, the chief technology officer now owns 121,503 shares of the company's stock, valued at approximately $2,048,540.58. This represents a 8.30 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.February 4, 2025 | marketbeat.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Gregory M. Weinhoff Sells 11,742 SharesJanuary 29, 2025 | insidertrades.comCentessa Pharmaceuticals chief business officer sells shares worth $193,429January 28, 2025 | msn.comInsider Selling: Centessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Sells 11,742 Shares of StockCentessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) insider Gregory M. Weinhoff sold 11,742 shares of Centessa Pharmaceuticals stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $16.47, for a total value of $193,390.74. Following the sale, the insider now owns 159,782 shares in the company, valued at $2,631,609.54. This trade represents a 6.85 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.January 28, 2025 | marketbeat.comCentessa Pharmaceuticals (NASDAQ:CNTA) Stock Price Down 3.4% - Should You Sell?Centessa Pharmaceuticals (NASDAQ:CNTA) Shares Down 3.4% - What's Next?January 24, 2025 | marketbeat.comAnalysts Conflicted on These Healthcare Names: Ironwood Pharma (IRWD) and Centessa Pharmaceuticals (CNTA)January 22, 2025 | markets.businessinsider.comJPMorgan Chase & Co. Has $2.17 Million Holdings in Centessa Pharmaceuticals plc (NASDAQ:CNTA)JPMorgan Chase & Co. lifted its stake in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 1,969.2% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 135,903 shares of the company's stock after buying an additional 1January 22, 2025 | marketbeat.comCentessa Pharmaceuticals (NASDAQ:CNTA) Trading 6.8% Higher - Here's WhyCentessa Pharmaceuticals (NASDAQ:CNTA) Shares Up 6.8% - What's Next?January 21, 2025 | marketbeat.comIqbal J. Hussain Sells 6,000 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) StockJanuary 18, 2025 | insidertrades.comCentessa Pharmaceuticals general counsel Hussain Iqbal sells $91,740 in sharesJanuary 17, 2025 | msn.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) General Counsel Sells $91,740.00 in StockCentessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) General Counsel Iqbal J. Hussain sold 6,000 shares of the firm's stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $15.29, for a total transaction of $91,740.00. Following the completion of the sale, the general counsel now owns 118,265 shares in the company, valued at $1,808,271.85. This represents a 4.83 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.January 17, 2025 | marketbeat.comIs Centessa Pharmaceuticals plc (CNTA) the Best Growth Stock to Buy Now Under $25?January 9, 2025 | insidermonkey.comCentessa Pharmaceuticals (NASDAQ:CNTA) Stock Price Down 10.5% - What's Next?Centessa Pharmaceuticals (NASDAQ:CNTA) Shares Down 10.5% - What's Next?January 8, 2025 | marketbeat.comCentessa Pharmaceuticals Appoints Stephen Kanes As CMOJanuary 8, 2025 | markets.businessinsider.comCentessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical OfficerJanuary 8, 2025 | globenewswire.comCentessa initiated with a Buy at TD CowenJanuary 8, 2025 | markets.businessinsider.comTD Cowen Initiates Coverage of Centessa Pharmaceuticals plc - Depositary Receipt () (CNTA) with Buy RecommendationJanuary 8, 2025 | msn.comCentessa Pharmaceuticals (NASDAQ:CNTA) Coverage Initiated by Analysts at TD CowenTD Cowen started coverage on shares of Centessa Pharmaceuticals in a report on Tuesday. They set a "buy" rating on the stock.January 7, 2025 | marketbeat.comState Street Corp Invests $777,000 in Centessa Pharmaceuticals plc (NASDAQ:CNTA)State Street Corp acquired a new stake in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 48,592 shares of the company's stock, valued atJanuary 3, 2025 | marketbeat.comCentessa Pharmaceuticals: Promising Market Position and Growth Potential in Orexin Agonists for NarcolepsyJanuary 3, 2025 | markets.businessinsider.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) Shares Could Be 30% Below Their Intrinsic Value EstimateJanuary 1, 2025 | finance.yahoo.comCentessa Pharmaceuticals (NASDAQ:CNTA) Stock Price Down 3.2% - What's Next?Centessa Pharmaceuticals (NASDAQ:CNTA) Trading Down 3.2% - Here's What HappenedDecember 31, 2024 | marketbeat.comCentessa Pharmaceuticals: Orexin Franchise Worth MonitoringDecember 31, 2024 | seekingalpha.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) Receives Average Recommendation of "Buy" from BrokeragesCentessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) has earned a consensus recommendation of "Buy" from the six brokerages that are presently covering the company, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy rating. The average 12 month price tarDecember 28, 2024 | marketbeat.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Gregory M. Weinhoff Sells 10,000 SharesDecember 27, 2024 | insidertrades.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Sells $170,400.00 in StockCentessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) insider Gregory M. Weinhoff sold 10,000 shares of the stock in a transaction on Thursday, December 26th. The shares were sold at an average price of $17.04, for a total value of $170,400.00. Following the completion of the sale, the insider now owns 183,266 shares in the company, valued at approximately $3,122,852.64. This trade represents a 5.17 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.December 26, 2024 | marketbeat.comCentessa Pharmaceuticals (NASDAQ:CNTA) Stock Price Down 3.8% - Here's What HappenedCentessa Pharmaceuticals (NASDAQ:CNTA) Shares Down 3.8% - Time to Sell?December 24, 2024 | marketbeat.comJane Street Group LLC Purchases Shares of 177,260 Centessa Pharmaceuticals plc (NASDAQ:CNTA)Jane Street Group LLC acquired a new position in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 177,260 shares of the company's stock, valued at appDecember 22, 2024 | marketbeat.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Saurabh Saha Sells 55,000 SharesDecember 21, 2024 | insidertrades.comInsider Selling: Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Sells $959,200.00 in StockCentessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) CEO Saurabh Saha sold 55,000 shares of the business's stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $17.44, for a total transaction of $959,200.00. Following the transaction, the chief executive officer now directly owns 520,661 shares of the company's stock, valued at $9,080,327.84. The trade was a 9.55 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.December 20, 2024 | marketbeat.comWhy Did Centessa Pharmaceuticals PLC (CNTA) Jump Yesterday?December 20, 2024 | msn.comWellington Management Group LLP Purchases New Stake in Centessa Pharmaceuticals plc (NASDAQ:CNTA)Wellington Management Group LLP bought a new stake in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 100,613 shares of the company's stock, valued at approximately $1,609December 19, 2024 | marketbeat.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Karen M. Anderson Sells 5,876 SharesDecember 18, 2024 | insidertrades.comFranklin Resources Inc. Grows Position in Centessa Pharmaceuticals plc (NASDAQ:CNTA)Franklin Resources Inc. grew its stake in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 99.1% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,302,546 shares of the company's stock after buying an additional 1December 18, 2024 | marketbeat.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Sells 5,876 SharesCentessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) insider Karen M. Anderson sold 5,876 shares of the company's stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $17.01, for a total transaction of $99,950.76. Following the completion of the transaction, the insider now owns 71,525 shares of the company's stock, valued at approximately $1,216,640.25. The trade was a 7.59 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.December 17, 2024 | marketbeat.comCentessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Karen M. Anderson Sells 10,624 SharesCentessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) insider Karen M. Anderson sold 10,624 shares of the firm's stock in a transaction dated Tuesday, December 17th. The stock was sold at an average price of $17.32, for a total value of $184,007.68. Following the sale, the insider now directly owns 71,525 shares in the company, valued at approximately $1,238,813. This represents a 12.93 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.December 17, 2024 | marketbeat.com Get Centessa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTA and its competitors with MarketBeat's FREE daily newsletter. Email Address CNTA Media Mentions By Week CNTA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CNTA News Sentiment▼0.340.60▲Average Medical News Sentiment CNTA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CNTA Articles This Week▼74▲CNTA Articles Average Week Get Centessa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies QGEN News ASND News ROIV News RVMD News LEGN News BBIO News AXSM News BPMC News TLX News ELAN News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CNTA) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Centessa Pharmaceuticals plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Centessa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CNTA Stock Alerts